Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells

Journal of Cellular Physiology

Volumn 228, Issue 4, 2013, Pages 764-772

  Benoit, Yannick D ^a   Laursen, Kristian B ^a   Witherspoon, Mavee S ^a   Lipkin, Steven M ^a   Gudas, Lorraine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; HISTONE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; RETINOIC ACID RECEPTOR BETA; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL CANCER; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOSINE; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; EPIGENOMICS; HISTONE-LYSINE N-METHYLTRANSFERASE; HT29 CELLS; HUMANS; MCF-7 CELLS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRETINOIN;

EID: 84871674660     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24224     Document Type: Article

References (42)

1. Amat R, Gudas LJ. 2011. RARgamma is required for correct deposition and removal of Suz12 and H2A.Z. in embryonic stem cells. J Cell Physiol 226:293-298.
2. Bastien J, Rochette-Egly C. 2004. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328:1-16.
3. Benoit YD, Lussier C, Ducharme PA, Sivret S, Schnapp LM, Basora N, Beaulieu JF. 2009. Integrin alpha8beta1 regulates adhesion, migration and proliferation of human intestinal crypt cells via a predominant RhoA/ROCK-dependent mechanism. Biol Cell 101:695-708.
4. Benoit YD, Pare F, Francoeur C, Jean D, Tremblay E, Boudreau F, Escaffit F, Beaulieu JF. 2010. Cooperation between HNF-1alpha, Cdx2, and GATA-4 in initiating an enterocytic differentiation program in a normal human intestinal epithelial progenitor cell line. Am J Physiol Gastrointest Liver Physiol 298:G504-G517.
5. Benoit YD, Lepage MB, Khalfaoui T, Tremblay E, Basora N, Carrier JC, Gudas LJ, Beaulieu JF. 2012. Polycomb repressive complex 2 impedes intestinal cell terminal differentiation. J Cell Sci 125:3454-3463.
6. Crea F, Paolicchi E, Marquez VE, Danesi R. 2012. Polycomb genes and cancer: Time for clinical application? Crit Rev Oncol Hematol 83:184-193.
7. de The H, Chen Z. 2010. Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10:775-783.
8. Dhandapani L, Yue P, Ramalingam SS, Khuri FR, Sun SY. 2011. Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer Res 71:5245-5254.
9. Gillespie RF, Gudas LJ. 2007. Retinoid regulated association of transcriptional co-regulators and the Polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells. J Mol Biol 372:298-316.
10. Glazer RI, Knode MC, Tseng CK, Haines DR, Marquez VE. 1986. 3-Deazaneplanocin A: A new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol 35:4523-4527.
11. Gudas LJ, Wagner JA. 2011. Retinoids regulate stem cell differentiation. J Cell Physiol 226:322-330.
12. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. 2010. Loss of miR-200 inhibition of Suz12 leads to Polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761-772.
13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
14. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B, Coetzee GA. 2008. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3:e3645.
15. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, Cheyette BN, Yu Q. 2008. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13:529-541.
16. Kashyap V, Gudas LJ, Brenet F, Funk P, Viale A, Scandura JM. 2011. Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. J Biol Chem 286:3250-3260.
17. Laursen KB, Wong PM, Gudas LJ. 2012. Epigenetic regulation by RARalpha maintains ligand-independent transcriptional activity. Nucleic Acids Res 40:102-115.
18. Lee MO, Han SY, Jiang S, Park JH, Kim SJ. 2000. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol 59:485-496.
19. Luis NM, Morey L, Di Croce L, Benitah SA. 2012. Polycomb in stem cells: PRC1 branches out. Cell Stem Cell 11:16-21.
20. Margueron R, Reinberg D. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469:343-349.
21. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. 2009. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8:1579-1588.
22. Mongan NP, Gudas LJ. 2005. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 4:477-486.
23. Mongan NP, Gudas LJ. 2007. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 75:853-870.
24. Nicke B, Kaiser A, Wiedenmann B, Riecken EO, Rosewicz S. 1999a. Retinoic acid receptor alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells. Biochem Biophys Res Commun 261:572-577.
25. Nicke B, Riecken EO, Rosewicz S. 1999b. Induction of retinoic acid receptor beta mediates growth inhibition in retinoid resistant human colon carcinoma cells. Gut 45:51-57.
26. Niederreither K, Dolle P. 2008. Retinoic acid in development: Towards an integrated view. Nat Rev Genet 9:541-553.
27. Paulsen JE, Lutzow-Holm C. 2000. In vivo growth inhibition of human colon carcinoma cells (HT-29) by all-trans-retinoic acid, difluoromethylornithine, and colon mitosis inhibitor, individually and in combination. Anticancer Res 20:3485-3489.
28. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, Batiste-Alentorn E, Lacy AM, Delgado S, Maurel J, Pique JM, Castells A. 2006. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:386-393.
29. Sauvageau M, Sauvageau G. 2010. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7:299-313.
30. Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, Aiwazian J, Sack R, Hess D, Li L, Zhou S, Bunker RD, Wirth U, Bouwmeester T, Bauer A, Ly-Hartig N, Zhao K, Chan H, Gu J, Gut H, Fischle W, Muller J, Thoma NH. 2011. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 42:330-341.
31. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW. 2002. The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem 277:25313-25322.
32. Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, Lipkin SM. 2010. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretary cell differentiation in colon cancer. Cancer Res 70:1469-1478.
33. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N. 2000. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 19:1556-1563.
34. Stolfi C, Caruso R, Franze E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G. 2011. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol Cancer Ther 10:1969-1981.
35. Sung B, Ravindran J, Prasad S, Pandey MK, Aggarwal BB. 2010. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285:35418-35427.
36. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. 2007. Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745-3757.
37. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. 2007. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050-1063.
38. Tang XH, Gudas LJ. 2011. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6:345-364.
39. Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M, Anzano M, Rieman D, Hoffstein S, Li DJ, Gennaro D, Buscarino C, Lynch M, Poste G, Russell G. 1988. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 41:287-296.
40. Youssef EM, Estecio MR, Issa JP. 2004. Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther 3:82-86.
41. Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237.
42. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, Lynch PM, Moyer MP, Wen XF, Wu X. 2010. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464:1058-1061.